NIKI Niki BioSolutions, Inc.
Measuring & Controlling Devices, NEC · Nasdaq · SEC CIK 1734005 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-66.7%
TTM net income YoY71.2%
TTM EPS YoY77.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin2.4%
Operating margin—
Net margin-654.8%
FCF margin-1,791.3%
EBITDA margin—
Returns
ROE-13.9%
ROA-13.6%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.73x
Accruals ratio23.6%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $352,879 | $2.20M |
| SG&A expense | $573,059 | $669,486 |
| Pretax income | -$1.38M | -$4.16M |
| Net income | -$1.36M | -$4.27M |
| EPS (basic) | -0.19 | -0.78 |
| EPS (diluted) | -0.19 | -0.78 |
| Weighted avg. shares (diluted) | 7.35M | 5.45M |
| Balance sheet | ||
| Cash & equivalents | $3.45M | $874,238 |
| Current assets | $3.59M | $959,554 |
| Total assets | $18.69M | $16.13M |
| Current liabilities | $4.59M | $4.34M |
| Total liabilities | $4.90M | $4.35M |
| Shareholders' equity | $23.12M | $21.13M |
| Cash flow statement | ||
| Operating cash flow | -$1.84M | -$1.19M |
| Investing cash flow | — | $58,621 |
| Financing cash flow | $4.42M | — |
| Depreciation & amortization | — | $255,046 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.